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An increasing body of evidence indicates that spontaneous and
treatment-induced apoptotic tumour cell death has wide implica-
tions for cancer therapy and as a prognostic factor (Wyllie, 1993;
Hannun, 1997). This has led to reconsider the mechanisms of how
tumour cells respond to cancer therapy (e.g. chemotherapy and
ionizing radiation (IR) (Fisher, 1994). Induction of DNA double-
strand breaks was considered as the major mechanism of IR-
induced cell death. However, more recent studies focus on
multiple IR-induced signal transduction cascades generated at the
plasma membrane, that trigger cells to undergo apoptosis
(Suzumiel, 1994; Maity et al, 1997).
The p53 tumour suppressor gene is a key element in the nucleus
to regulate normal cell cycle activity and is often cited to be the
‘guardian of the genome’. p53 is one of the most frequently
mutated genes in advanced human cancer and, if mutated, is often
an inverse prognostic factor for outcome (Harris, 1996; Maity et
al, 1997). p53 is activated upon DNA damage and, in response to
other cytotoxic agents and can enhance the cytotoxic effect of IR
through apoptosis induction in many human malignancies (Ruley,
1996).
The sphingomyelin pathway is an important apoptotic cell death
pathway that is generated at the cell membrane by various triggers,
e.g. IR, tumour necrosis factor (TNF)-a and Fas/Apo-1 (Obeid et
al, 1993; Haimovitz-Friedman et al, 1994; Herr et al, 1997). This
pathway is initiated by hydrolysis of sphingomyelin by specific
phospholipases (sphingomyelinases) to generate the intracellular
apoptotic second messenger ceramide. Activation of the sphin-
gomyelin pathway and subsequent generation of ceramide by IR
was shown to be independent of DNA damage (Haimovitz-
Friedman et al, 1994). The second messenger ceramide has been
shown to activate the stress-induced apoptotic JNK/SAPK cascade
in some cell systems and is also involved in the coordination of
cytokine-induced apoptotic pathways (Chinnaiyan et al, 1996;
Verheij et al, 1996; Haimovitz-Friedman et al, 1997). Furthermore,
ceramide has been shown to induce cytochrome C release from
mitochondria in acute myeloid leukaemia cells to activate caspase
3-like activity (Amarante-Mendes et al, 1998).
In this study we investigated if the p53 status of tumour cells
can modulate the apoptotic response upon activation of the sphin-
gomyelin pathway. For this purpose we used a cell-permeable
ceramide derivative or neutral sphingomyelinase (nSMase) in a
genetically defined tumour system with a strict p53-dependent
response to IR and various chemotherapeutic agents (Jacks et al,
1994; Lowe et al, 1994a).
MATERIALS AND METHODS
Cell culture and irradiation
Cell lines of p531/1 and p532/2 mouse embryo fibroblasts
(MEF) were derived from 13.5-day-old embryos and transformed
by co-expression of E1A and T24 H-ras (referred to in the manu-
script as ras) (Lowe et al, 1993b). These oncogenically trans-
formed fibrosarcoma cells were used at low passage numbers and
cultured at 5% carbon dioxide atmosphere in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS)
and 10% bovine calf serum (BCS) (HyClone Laboratories) supple-
mented with penicillin and streptomycin. The characteristic p53-
dependent response to ionizing radiation and apoptosis induction
of these tumour cells were verified monthly. Irradiation of the cells
was carried out at room temperature in tissue culture dishes
(100  3 100 mm) with a 6 MV linear accelerator at a dose rate of
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Summary p53 mutations are among the most common genetic alterations in human cancer and are frequently described in intrinsic or
acquired radio- and chemotherapy resistance. Radiation-induced cell kill is not only mediated by DNA damage but also by the activation of
signal transduction cascades generated at the plasma membrane like the sphingomyelin pathway. We used genetically defined wild-type p53
or p53-deficient mouse fibrosarcoma cells to investigate the p53-dependence of tumour response upon activation of the sphingomyelin
pathway. Treatment of the tumour cells with neutral sphingomyelinase drastically reduced the amount of wild-type p53 fibrosarcoma cell
proliferation over 72 h in a clear dose–response (0.2–1.0 U ml21 nSMase). Sphingomyelinase had no effect on cell proliferation in tumour cells
lacking p53. Similarly, cell proliferation was abolished by C2-ceramide (5–20 mM) only in wild-type p53 cells. FACS-analysis revealed that C2-
ceramide induced massive p53-dependent apoptosis (40–50% after 12–24 h) and cell cycle analysis showed a transient G1 arrest in p53-
deficient tumour cells 12–24 h after C2-ceramide exposure. These results suggest that ceramide-induced apoptosis in tumour cells can be
dependent on the status of p53 and imply that p53 is also important for stress-induced apoptotic signal transduction cascades generated at
the plasma membrane.
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Correspondence to: S Bodis2 Gy per min. Dosimetry was controlled with a Vigilant-
dosimeter. A 9 mm bolus on the tissue culture dishes was used
for a build-up effect.
Cell proliferation and clonogenic assay
The cell permeable C2-ceramide (N-acetylsphingosine) and the
metabolically inactive C2-dihydroceramide (N-acetyldihydro-
sphingosine) were purchased from BIOMOL (Plymouth Meeting,
PA, USA), the enzyme neutral sphingomyelinase derived from
Staphylococcus aureus from Sigma (St Louis, MO, USA).
Dissolved C2-ceramide (in dimethyl sulphoxide) and C2-dihydro-
ceramide (in EtOH) was diluted in DMEM to the final concentra-
tion. nSMase was diluted in serum-free medium. For the
experiments, cells were washed in serum-free medium and incu-
bated with the drugs for 6 h in DMEM containing 0.5% FCS. After
6 h, serum was added to the final concentration of 20%. Tumour
cell proliferation was assessed by the colourimetric alamarBlue
assay that is based on detection of metabolite activity according to
the protocol of the manufacturer (Biosource International,
Camarillo, CA, USA). Absorption was measured at 570 and 600
nm using a Dynatech MR5000 spectrophotometer. To determine
clonogenic survival, the number of singular cells plated was
adjusted to obtain about 100 colonies per dish with a given treat-
ment. After exposure to the different drugs, cells were maintained
at 378C in a humidified atmosphere containing 5% carbon dioxide.
Cells were then allowed to grow for 8–10 days before fixation in
methanol/acetic acid (75%/25%) and staining with crystal violet.
Only colonies with more than 50 cells per colony were counted.
The plating efficiency (PE) of untreated cells was determined and
calculated by PE (%) 5 (scored colonies/number of plated cells)
3 100. The surviving fraction (SF) with a given treatment was
determined by SF 5 (scored colonies) / (number of plated cells 3
PE/100).
Quantification of apoptosis and cell cycle analysis
Cells were prepared for apoptosis and cell cycle analysis using
flow cytometry (Darzynkiewic, 1995). Briefly, adherent and
floating cells were collected at different time points, fixed with
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Figure 1 Proliferation of fibrosarcoma cells after sphingomyelin pathway activation. Wild type p53 (A, C) and p53-deficient (B, D) fibrosarcoma cells were
treated with increasing concentrations of nSMAse (A, B), C2-ceramide (Cer) or C2-dihydroceramide (Dihydrocer) (C, D) and proliferation was detected at
different time points after drug addition with the alamarBlue assay. At least two independent experiments were performed in triplicates. Absence of error bars is
due to minimal standard deviation70% ethanol overnight at 2208C, washed with HBSS and resus-
pended in 1 ml of HBSS containing 50 u DNAase-free RNAase A
per ml and propidium iodine (20 mg ml21). FACS analysis was
performed on a FACScan (Becton Dickinson) and data of the
different cell populations were analysed using Cell Quest software
(Becton Dickinson). At least three independent experiments were
performed for each set of data. For cell cycle quantification, the
amount of apoptotic cells were subtracted from the total cell popu-
lation and the amount of surviving cells are shown as 100%.
RESULTS
Inhibition of cell proliferation after sphingomyelin
pathway activation is p53-dependent
Cell proliferation after induction of the sphingomyelin pathway
was determined in transformed fibrosarcoma cells. This tumour
cell system consists of E1A/ras transformed mouse embryo
fibroblasts from either wild-type (1/1) or p53-knockout (–/–)
mice and was previously described for its strict p53-dependent
response to treatment with IR and different cytotoxic drugs in vitro
and in vivo using nude mice as tumour carriers (Lowe et al,
1994a). Activation of the sphingomyelin pathway was achieved
either by treatment of the cells with bacterial nSMase and subse-
quent generation of the apoptotic second messenger ceramide, or
by the addition of membrane-permeable C2-ceramide.
Increasing doses of nSMase drastically reduced proliferation of
wild-type p53 fibrosarcoma cells as assessed with the alamarBlue
assay, a proliferation assay comparable to tetrazolium salt based
(MTT-assay) quantification of cell metabolism. Proliferation was
reduced in a clear dose–response and no metabolic activity was
detected for at least 72 h after treatment with 0.8 U ml21 of SMase
(Figure 1A). In the p53-deficient fibrosarcoma cells, cell prolifera-
tion was maximally reduced by 27%, even after treatment with
high doses of SMase (Figure 1B).
In comparison to nSMase concentrations used in leukaemic cell
lines for sphingomyelin pathway activation and apoptosis induction,
tenfold higher concentration of nSMase (0.6 and 0.8 U ml21 of
nSMase) was required to reduce the proliferation of the wild-type
p53 fibrosarcoma cells. This could be due to a different lipid compo-
sition of this cell type or a restricted accessibility of nSMase to the
cell membrane of adherent cells. Higher doses of nSMase were also
required for sphingomyelinase-induced apoptosis in adherent
bovine aortic endothelial cells (Haimovitz-Friedman et al, 1994).
To bypass differences in ceramide generation by nSMase due to
possible variations of the cellular lipid composition, subsequent
studies on cell proliferation were also performed with the synthetic
and cell-permeable ceramide analogue N-acetyl-sphingosine (C2-
ceramide). C2-ceramide (5 mM) reduced the amount of prolifera-
tion in the wild-type p53 tumour cells up to 50% and at higher
concentrations of C2-ceramide (10 and 20 mM respectively), no
proliferative activity could be detected for at least 96 h. These
concentrations of C2-ceramide are in the range as previously used
for other cell lines (Figure 1C) (Jarvis et al, 1996). A reduction of
p53–/– tumour cell proliferation was only observed at the highest
C2-ceramide concentration of 20 mM used for these experiments.
Lower doses of C2-ceramide (5 and 10 mM) revealed no growth
inhibition in this relatively radio- and chemoresistant cell line
(Figure 1D). The metabolically inactive dihydro-C2-ceramide
analogue had no effect on cell proliferation in both cell lines. Thus,
decreased tumour cell proliferation after activation of the sphin-
gomyelin pathway either by the nSMase or by cell-permeable C2-
ceramide was dependent on the p53 status of the cell.
Next, we determined the effect of sphingomyelin pathway acti-
vation on the clonogenic survival of the wild-type p53 and p53-
deficient tumour cells. Singular seeded wild-type p53 and
p53-deficient fibrosarcoma cells were allowed to grow for 8–10
days in presence of nSMase (1 U ml21) or C2-ceramide (20 mM), at
concentrations which revealed a distinct p53-dependent difference
in proliferation as described above. Tumour cell colony formation
of the wild-type p53 and p53-deficient cells after treatment with
nSMase or C2-ceramide was compared to colony formation after
irradiation (Figure 2). Whereas nSMase treatment of the p53–/–
cells had almost no effect on the reproductive integrity, a reduction
in colony formation of 25% and 40%, respectively, was observed
after treatment with 20 mM C2-ceramide and 5 Gy IR. In the
p531/1 tumour cells, colony formation after nSMase and irradia-
tion was reduced to 65% and C2-ceramide treatment reduced
clonogenic survival up to 90% (mean values of several indepen-
dent experiments, see legend to Figure 2). Thus, similar to the
response to irradiation, sphingomyelin pathway activation strongly
reduced clonogenic survival of wild-type p53 tumour cells but not
of p53-deficient cells. Interestingly, the difference in cell survival
between the two cell lines was even more distinct after sphin-
gomyelin pathway activation than after treatment with 5 Gy IR.
We tested whether decreased proliferation and reduced clono-
genic survival in the wild-type p53 tumour cells after ceramide
exposure was due to p53-dependent induction of apoptosis.
Characteristic morphological changes suggestive for apoptosis,
such as chromatin condensation and nuclear fragmentation, were
detected in the wild-type p53 cells after IR or C2-ceramide treat-
ment and were only incidentally found in p53-deficient cells (data
not shown). The amount of apoptosis in the different cell lines was
quantified by flow cytometry. The p531/1 and p53–/– fibrosar-
coma cells were treated with C2-ceramide (20 mM) and analysed
for apoptosis 12 and 24 h after drug addition. In the p53-deficient
cell population, increase of ceramide-induced apoptosis was less
than 5% of the total cell population at different time points (Figure
Ceramide induces p53-dependent apoptosis 695
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Figure 2 Clonogenic survival of fibrosarcoma cells after sphingomyelin
pathway activation and irradiation. Singular seeded p531/1 and p53–/– cells
were treated with nSMAse (1 U ml21), C2-ceramide (20 mM) or IR (5 Gy) and
allowed to grow for 8–10 days. All experiments were performed in triplicates.
Absence of error bars is due to minimal standard deviation3). However, treatment of the p531/1 cells with C2-ceramide
increased the amount of apoptotic cells up to 45% of the whole cell
population. Beyond 24 h, the amount of apoptotic cells declined
(data not shown).
In addition to the induction of apoptosis, treatment of cells with
ceramide can also lead to growth arrest. We examined the p53-
deficient, but otherwise isogenic, E1A/ras transformed tumour
cells for ceramide-induced cell cycle alterations. Treatment with
C2-ceramide induced a transient accumulation of cells in G1
phase. The maximal accumulation of cells in the G1 phase was
observed 12 h after C2-ceramide exposure (mean increase 37%
(±0.6%) to 47% (±2.9%) and declined thereafter. In accordance
with the increasing cell distribution into G1, a decreasing fraction
of cells in S and G2/M phase was identified (Figure 4).
Interestingly, we could not reveal any cell cycle alterations upon
C2-ceramide exposure in the surviving wild-type p53 cell popula-
tion that did not undergo apoptosis (data not shown).
DISCUSSION
Activation of the sphingomyelin pathway specifically reduced
proliferation and clonogenicity in the chemo- and radiation
therapy-sensitive, wild-type p53 tumour cells due to the induction
of apoptosis. These results imply that p53 is involved in the
cellular response to ceramide, a specific inducer of apoptosis, that
is independent of DNA damage.
The sphingomyelin–ceramide pathway can be activated by
treatment of cells with TNF-a, low density lipoproteins and
hydrogen peroxide. A partial p53-dependent effect on cell survival
has been observed in differentiated macrophages treated with
these agents (Kinscherf et al, 1998). Preincubation with p53-anti-
sense oligonucleotides reduced oxidative stress-dependent up-
regulation of p53 and decreased the amount of apoptosis by about
20%. In our cell system, we demonstrate that genetically defined
tumour cells, differing only in their p53 status, have a different
response to direct ceramide treatment. Ceramide strongly induced
apoptosis in the wild-type p53, but not in the isogenic, p53-defi-
cient, tumour cells.
Both p531/1 and p53–/– mouse embryo fibroblasts are trans-
formed by co-expression of E1A and ras. We can not exclude that
transformation of these cells might lead to subsequent genetic
alterations. But such changes could also reflect the processes in
carcinogenesis in wild-type p53 and p53-mutated tumours leading
to different phenotypes still primarily dependent on the p53 status
for their treatment response.
Previously, Lowe et al (1994b) demonstrated that the p53 level
in the wild-type p53 tumour cells used for these studies, is
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Figure 3 C2-ceramide-induced apoptosis in fibrosarcoma cells as determined by flow cytometry. Tumour cells were incubated with C2-ceramide (20 mM) and
the amount of apoptosis was determined 12 and 24 h, respectively, after drug addition. At least two independent experiments were performed
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Figure 4 Partial G1 arrest of p53–/– fibrosarcoma cells after C2-ceramide
addition. p53–/– tumour cells were treated with C2-ceramide (20 mM) and cell
cycle distribution was determined 12 and 24 h after drug addition. At least
three independent experiments were performed and absence of error bars is
due to minimal standard deviationup-regulated upon E1A/ras transformation. Serum depletion of the
cells did not further increase the p53 level, but induced apoptosis
in the wild-type p53 tumour cells (Lowe et al, 1994b). Growth
factor withdrawal can result in significant sphingomyelin hydrol-
ysis and progressive elevation of endogenous levels of ceramide
(Hannun and Linardic, 1993; Jayadev et al, 1995). These findings
suggest that ceramide might be the pivotal mediator for the
observed p53-dependent apoptosis induction upon growth factor
deprivation in this tumour cell system.
Stress factors may induce apoptosis by up-regulating pro-apop-
totic or down-regulating anti-apoptotic processes. p53 is a direct
transcriptional activator of the pro-apoptotic bax gene (Miyashita
and Reed, 1995). In addition, growth factor deprivation and
elevated ceramide levels result in the down-regulation of Akt
kinase. Active Akt blocks BAD-mediated cell death via phos-
phorylation of BAD and, presumably, subsequent reduction of
Bax-homodimer formation (Datta et al, 1997; Zhou et al, 1998;
Zundel and Giacca, 1998). Thus, induction of apoptosis by stress
factors including IR might be mediated by different though co-
operating signal transduction processes.
We observed a transient G1 arrest in the p53-deficient tumour
cells after sphingomyelin pathway activation. Similarly, a G1
arrest of the cell cycle induced by ceramide has been observed in
the B lymphoma Raji cells, Hs-27 cells, and Molt-4 cells.
Mechanistically, ceramide-induced cell cycle arrest has been
linked to an underphosphorylated state of the retinoblastoma
protein, pRb, thereby preventing further progression through the
S phase upon sequestration of the transcription factor E2F
(Jayadev et al, 1995; Kuroki et al, 1996; Alesse et al, 1998). It
might be interesting to exploit an even stronger induction of a p53-
independent G1 arrest via dose escalation studies with ceramide or
drugs interacting with the ceramide pathway in combination with
other cytotoxic agents. Specific inhibitors against protein kinase C,
which interferes with the sphingomyelin pathway, might be inter-
esting candidates for such investigations (Chmura et al, 1997;
Tsuchida and Urano, 1997).
Differences in the apoptotic response after g-irradiation in the acid
sphingomyelinase knockout mice compared to the response in p53
knockout animals suggested that p53- and ceramide-mediated apop-
tosis are likely distinct and independent (Santana et al, 1996).
Furthermore, ceramide-induced apoptosis has been demonstrated in
p53-deficient tumour cells, that rapidly undergo apoptosis as stress
response to different treatments (e.g. HL-60 cells) (Jarvis et al,
1994). However, the role of sphingomyelinase and p53 for stress-
induced apoptosis can vary among various tumour cells and even
more so can be different from their untransformed origins (Obeid et
al, 1993; Santana et al, 1996). p53-dependent apoptosis in response
to ionizing radiation occurs to a large extent only in tumour cells and
in cells prone to undergo apoptosis like primary thymocytes (Clarke
et al, 1993; Lowe et al, 1993a). Our defined cell system is derived
from mouse embryo fibroblasts, that in an untransformed status,
regardless of the p53 status, does not undergo apoptosis upon
irradiation but acquires its strict p53-dependent apoptotic response
to chemo- and radiotherapeutical treatment upon oncogenical trans-
formation (Lowe et al, 1993a, 1994b). Thus, the different p53-
dependent biological response to the second messenger ceramide as
presented in this study is similar to the difference in chemo- and
radiosensitivity observed in multiple human tumours with wild-type
and mutated p53 status in vitro and in vivo.
The role of p53 in apoptosis induction has been mainly studied
upon DNA-damaging chemotherapeutical drugs and irradiation.
However, IR also activates specific signal transduction cascades
generated at the plasma membrane. Our results suggest that p53 is
not only important in the cellular response to DNA damage, but
also for the cellular response to specific apoptotic signal transduc-
tion cascades like the sphingomyelin pathway, generated at the
plasma membrane.
ACKNOWLEDGEMENTS
This work was supported by Grants from the Swiss Cancer
League, the Zurich Cancer League and the Radiumstiftung (to SB)
and the Sassella Foundation (to Y-QS).
REFERENCES
Alesse E, Zazzeroni F, Angelucci A, Giannini G, Di Marcotullio L and Gulino A
(1998) The growth arrest and downregulation of c-myc transcription induced
by ceramide are related events dependent on p21 induction, Rb
underphosphorylation and E2F sequestering. Cell Death Diff 5: 381–389
Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR
and Bhalla K (1998) Bcr-abl exerts its antiapoptotic effect against diverse
apoptotic stimuli through blockage of mitochondrial release of cytochrome C
and activation of caspase-3. Blood 91: 1700–1705
Chinnaiyan AM, Orth K, O’Rourke K, Duan H, Poirier GG and Dixit VM (1996)
Molecular ordering of the cell death pathway: Bcl-2 and Bcl-xL function
upstream of the CED-3 like apoptotic proteases. J Biol Chem 271: 4573–4576
Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J and Weichselbaum RR
(1997) Loss of ceramide production confers resistance to radiation-induced
apoptosis. Cancer Res 57: 1270–1275
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie
AH (1993) Thymocyte apoptosis induced by p53-dependent and independent
pathways. Nature 362: 849–852
Darzynkiewic Z (1995) In: Cell Growth and Apoptosis, Sudzinski GP. Oxford
University Press: Oxford
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME (1997)
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death
machinery. Cell 91: 231–241
Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78:
539–542
Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLouglin M, Fuks Z and
Kolesnick RN (1994) Ionizing radiation acts on cellular membranes to generate
ceramide and induce apoptosis. J Exp Med 180: 525–535
Haimovitz-Friedman A, Kolesnick RN and Fuks Z (1997) Ceramide signaling in
apoptosis. Br Med Bull 53: 539–553
Hannun YA and Linardic CM (1993) Sphingolipid breakdown products: anti-
proliferative and tumor-suppressor lipids. Biochim Biophys Acta 1154: 223–236
Hannun YH (1997) Apoptosis and the dilemma of cancer chemotherapy. Blood 89:
1845–1853
Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for
rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442–1455
Herr I, Wilhelm D, Böhler T, Angel P and Debatin KM (1997) Activation of CD95
(Apo-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.
EMBO J 16: 6200–6208
Jacks T, Remington L, Williams B, Schmitt E, Halachmi S, Bronson R and Weinberg
R (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7
Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA and Grant S (1994)
Induction of apoptotic DNA damage and cell death by activation of the
sphingomyelin pathway. Proc Natl Acad Sci USA 91: 73–77
Jarvis WD, Grant S and Kolesnick RN (1996) Ceramide and the induction of
apoptosis. Clin Cancer Res 2: 1–6
Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva MY, Obeid LM and
Hannun YA (1995) Role for ceramide in cell cycle arrest. J Biol Chem 270:
2047–2052
Kinscherf R, Claus R, Wagner M, Gehrke C, Kamencic H, Hou D, Nauen O,
Schmiedt W, Kovacs G, Pill J, Metz J and Deigner HP (1998) Apoptosis caused
by oxidized LDL is manganese superoxide dismutase and p53 dependent.
FASEB J 12: 461–467
Kuroki J, Hirokawa M, Kitabayashi A, Lee M, Horiuchi T, Kawabata Y and Miura
AB (1996) Cell permeable ceramide inhibits the growth of B lymphoma Raji
cells lacking TNF-alpha-receptors by inducing G0/G1 arrest but not apoptosis:
Ceramide induces p53-dependent apoptosis 697
British Journal of Cancer (1999) 80(5/6), 693–698 © Cancer Research Campaign 1999a new model for dissecting cell-cycle arrest and apoptosis. Leukemia 10:
1950–1958
Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993a) p53 is required
for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847–849
Lowe SW, Ruley HE, Jacks T and Housman DE (1993b) p53-dependent apoptosis
modulates the cytotoxicity of anticancer agents. Cell 74: 957–967
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman
DE and Jacks T (1994a) p53 can determine the efficacy of cancer therapy in
vivo. Science 266: 807–810
Lowe SW, Jacks T, Housman DE and Ruley HE (1994b) Abrogation of oncogene-
associated apoptosis allows transformation of p53-deficient cells. Proc Natl
Acad Sci USA 91: 2026–2030
Maity A, Kao GD, Mische RJ and McKenna WG (1997) Potential molecular targets
for manipulating the radiation response. Int J Radiat Oncol Biol Phys 37:
639–653
Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional
activator of the human bax gene. Cell 80: 293–299
Obeid LN, Linardic CM, Karolak LA and Hannun YA (1993) Programmed cell
death induced by ceramide. Science 259: 1769–1771
Ruley HE (1996) In: Important Advances in Oncology, DeVita VT, Hellmann S and
Rosenberg SA (eds). Lippincott: Philadelphia
Santana P, Pena LA, Haimovitz-Friedman A, McLoughlin M, Cordon-Carlo C,
Schuchman EH, Fuks Z and Kolesnick R (1996) Acid sphingomyelinase-
deficient human lymphoblasts and mice are defective in radiation-induced
apoptosis. Cell 86: 189–199
Suzumiel I (1994) Review: Ionizing radiation-induced cell death. Int J Radiat Oncol
Biol Phys 66: 329–341
Tsuchida E and Urano M (1997) The effect of UCN-01 (7-hydroxystaurosporine), a
potent inhibitor of protein kinase C, on fractionated radiotherapy or daily
chemotherapy of a murine fibrosarcoma. Int J Radiat Oncol Biol Phys 39:
1153–1161
Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon I,
Kyriakis JM, Haimovitz-Friedman A, Fuks Z and Kolesnick RN (1996)
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced
apoptosis. Nature 380: 75–79
Wyllie AH (1993) Apoptosis (The Frank Rose Memorial Lecture). Br J Cancer 67:
205–208
Zhou H, Summers SA, Birnbaum MJ and Pittman RN (1998) Inhibition of Akt
kinase by cell-permeable ceramide and its implications for ceramide-induced
apoptosis. J Biol Chem 27: 16568–16575
Zundel W and Giaccia A (1998) Inhibition of the anti-apoptotic PI(3)K/Akt/Bad
pathway by stress. Genes Dev 12: 1941–1946
698 M Pruschy et al
British Journal of Cancer (1999) 80(5/6), 693–698 © Cancer Research Campaign 1999